Updates are available Correction dated 2021-07-09

Article History

Received: 11 February 2020

Accepted: 10 March 2020

First Online: 17 March 2020

Change Date: 9 July 2021

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s41999-021-00528-x

Compliance with ethical standards

:

: LM has nothing to declare. MW was employed by AstraZeneca R&D, Mölndal, as director of discovery medicine (= translational medicine) from 2003 to 2006, while on sabbatical leave from his professorship at the University of Heidelberg. Since returning to this position in January 2007, he has received lecturing and consulting fees from Sanofi-Aventis, Bayer, Berlin-Chemie, Boehringer-Ingelheim, Aspen, Novartis, Takeda, Roche, Pfizer, Bristol-Myers, Daichii-Sankyo, Lilly, Otsuka, Novo-Nordisk, Shire and LEO Pharma. In addition, the FORTA classification was developed by M.W.

: Ethical approval was not necessary as no patient data were analysed.

: Informed consent was obtained from all participant.